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EDITORIAL Open Access
From genes to genomes in the clinic
Joris A. Veltman1,2* and James R. Lupski3,4
Editorial summary
Next-generation sequencing is revolutionizing
medical genetics and in the near future will pervade
all medical fields. To maximize the potential clinical
utility of this approach, global data sharing and
phenotyping are needed, and the role of the
geneticist in the interpretation of variation is vital.
Towards single-test genomics
Medical genetics is experiencing an exciting and disrup-
tive technological revolution. Next-generation sequen-
cing (NGS) technologies are enabling simultaneous
sequencing of all relevant disease genes, the exome or
even the entire genome of patients seeking a molecular
diagnosis. This can be performed on small sample vol-
umes and even single cells with near-perfect accuracy, in
days rather than months, and at more and more afford-
able pricing, allowing widespread implementation in the
clinic [1]. This is an important moment in the history of
medical genetics, because for the first time we can study
a person’s entire genome in our quest to find the genetic
causes underlying disease and/or those potentially
having an impact on clinical response to treatment.
Genome sequencing, although still imperfect, will en-
able the detection of all types of genomic variation in a
single experiment, including point mutations or single
nucleotide variants, insertion-deletions, repeat expansions
and larger structural variations such as copy number
variants and copy-number-neutral inversions and translo-
cations. Although genome sequencing is currently more
expensive than targeted disease gene or exome sequencing
as calculated on a per test basis, this may not be the case
when calculated on a per patient basis. Pilot studies have
already demonstrated that genome sequencing can reveal
causative mutations or structural variations missed by
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other genetic tests, including Sanger sequencing, exome
sequencing and genomic microarrays [2, 3]. Regardless of
which NGS approach is used, it is evident that variant
identification is becoming more and more readily attain-
able, whereas variant interpretation in each individual
patient remains a major challenge [4, 5]. This has consid-
erable consequences for medical genetics laboratories,
where there will be less need for expertise in laboratory
data generation and increased demand and necessity for
expert data analysis and interpretation.
Single-test or comprehensive genetic testing, such as
that provided by genome sequencing, has many important
advantages in the clinic. It allows automated laboratory
procedures and standardization of variant calling and
reporting. No longer is a subjective clinical decision
required to determine which genetic test to perform and
in which patient. Instead, implementation of a single
genetic test is sufficient. It is conceivable that best practice
will evolve to a point at which genome sequencing will be
performed before a patient even visits a clinician. This
may enable the clinician to capitalize on the genomic
information immediately and use it to form a diagnosis.
Comprehensive genomic sequencing requires a diffe-
rent skill set for clinical geneticists and other medical
professionals using genetic data. The genomic data
from patients, collected in a standardized format all
over the globe, will be enormously valuable to improve
our understanding of variant pathogenicity and disease
susceptibility. Data sharing on a global scale is there-
fore essential to improved understanding of genotype–
phenotype correlations [6]. Global data sharing is not
just a lofty goal but rather a requirement for under-
standing human biology and deviations from homeosta-
sis or health; it transcends geographic, political and
religious boundaries that can sometimes divide the
human race. These genomic data are, however, useful
only if combined with phenotypic information collected
in a standardized manner as well. It is remarkable to
think that genome sequencing itself may soon turn out
to be the easy part of the equation. Standardized phe-
notyping all over the world is likely to be a major chal-
lenge required for maximizing the medical knowledge
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acquisition from personal genomic variant information.
This requires clinicians to adapt their clinical practice
and potentially adopt and incorporate novel phenotyp-
ing tools.
Clearly, there are ethical and legal issues related to
medical genome sequencing. These are mostly related to
ownership and privacy of personal data and the risk of
detecting clinically relevant genomic variants unrelated
to the original clinical conundrum and concern for
which the patient visited the clinician [7]. Patients need
to be protected from misuse of their genomic data and
need to be adequately counseled so that they can under-
stand the information contained in their genome and
the current limitations of medical knowledge. In this re-
gard, an obligation of the community of geneticists and
genomicists will be to educate the physicians, patients
and public about DNA, the genetic code, genomics and its
role in human biology, health and disease susceptibility.
The growth of genome sequencing capacity is impressive
by any measure, with commercial platforms now being
able to sequence 10,000–50,000 genomes per year. This
has spurred a range of national programs, such as the
100,000 Genomes Project in the United Kingdom (http://
genomicsengland.co.uk), FarGen (http://www.fargen.fo/
en) in the Faroe Islands, and the precision medicine initia-
tives in the USA (http://www.nih.gov/precisionmedicine/)
and Saudi Arabia (http://shgp.kacst.edu.sa/site/). At the
same time, individual medical genetics laboratories around
the globe are learning to interpret individual variation ob-
tained from targeted disease gene and exome sequencing
in their clinics on a daily basis.
Clinical genomics
Rapid, accurate, comprehensive and affordable NGS
approaches are desperately needed to realize the many
promises of personalized or precision medicine. Tradition-
ally, genetics has had a major role in diagnosing rare
disease and hereditary forms of cancer, as well as in pre-
natal testing for Down syndrome. As a result, NGS
approaches are first replacing Sanger sequencing and gen-
omic microarrays for these applications because of their
higher diagnostic yield and non-invasive application. The
higher diagnostic yield of NGS approaches also results in
an expansion of medical conditions for which genetic
testing is being considered. For many of these disorders,
such as immune deficiencies and autism spectrum disor-
ders, it was known that genetics has a role in a significant
percentage of cases. Their genetic heterogeneity, however,
requires the comprehensiveness of NGS.
A rapid turn-around time is even more important for de-
termining the right cancer therapy, for residual disease
monitoring, and in neonatal intensive care units [8].
Sequencing of cancer genomes may soon become a stand-
ard diagnostic procedure, similar to a histopathological
evaluation, but different in that it can be applied on mul-
tiple occasions to determine remission and resistance to
therapy. Cancer researchers are accumulating evidence that
this will guide individual therapy to the most effective can-
cer drugs, and speed up drug repurposing as well as novel
drug target discovery [9]. Getting the right amount of the
right drug to the right patient is a challenge in most of
medicine. Pharmacogenetics is currently underused in
medicine, even though there are more than 100 drugs for
which genetic testing is recommended. The possibility of
offering a comprehensive, affordable and rapid NGS-based
test is likely to be of great benefit for pharmacogenetics as
well [10]. In a prenatal setting, non-invasive screening for
trisomies using NGS approaches is only a first step. Pilot
studies, although complex and expensive, have shown the
possibilities to sequence the genome of the fetus with all
its variation [11]. An alternative could be to offer precon-
ception screening to couples, and again NGS approaches
are now allowing this to be done comprehensively for all
known recessive conditions [12]. Interpretation of these
genomic data to predict disease is much more complex in
a prenatal or preconception setting than it is in a postnatal
setting. Predicting the age of onset or severity of disease is
even more complex in a prenatal setting. In addition, for
many severe early-onset disorders such as intellectual dis-
ability, we have recently learned that the condition is often
caused by de novo mutations [3], which would be missed
by preconception screening. It is unknown to what extent
prenatal or preconception genetic screening will be imple-
mented or sought, but the technology is making these into
realistic options.
In conclusion, it is not hard to imagine a near future
in which genomics is pervasive throughout medicine, in
many subspecialties and in general practice. The human
genetics and genomics field will change, but geneticists
are needed more now than ever, working together with
other medical specialties to provide clinically relevant
genomic information and medical knowledge, with a
common goal: to improve patient care.
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